EWTX
Edgewise Therapeutics, Inc.
Price Chart
Latest Quote
$36.94
+0.12 (+0.34%)
Current Price
| Previous Close | $36.81 |
| Open | $37.03 |
| Day High | $37.44 |
| Day Low | $35.96 |
| Volume | 459,213 |
Stock Information
| Shares Outstanding | 107.59M |
| Total Debt | $3.79M |
| Cash Equivalents | $499.56M |
| Net Income | $-176.01M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.97B |
| EPS (TTM) | $-1.66 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $3.46B |
| Income | $-176.01M |
| Book/sh | $4.59 |
| Cash/sh | $4.64 |
| Employees | 154 |
Financial Ratios
| Quick Ratio | 22.16 |
| Current Ratio | 22.61 |
| Debt/Eq | 0.77 |
Returns & Margins
| ROA | -25.64% |
| ROE | -38.14% |
Ownership
| Insider Ownership | 0.45% |
| Institutional Ownership | 113.98% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -25.92 |
| P/B | 8.05 |
Analyst Data
| Recommendation | buy |
| Target Price | $48.17 |
Technical Indicators
| SMA20 | $35.11 |
| SMA50 | $33.87 |
| SMA200 | $26.10 |
| RSI | 39.55 |
| ATR | 2.5191 |
| Shares Float | 67.12M |
| Short Float | 14.35% |
| Short Ratio | 8.58 |
| Volatility | 0.30 |
| Rel Volume | 0.25 |
Performance History
| Week | +6.04% |
| Month | +12.54% |
| Quarter | +27.10% |
| 6 Months | +65.55% |
| YTD | +55.52% |
| Year | +155.25% |
| 3 Years | +287.97% |
| 5 Years | +41.89% |
| 10 Years | +23.12% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $36.94 | 459,213 |
| 2026-06-18 | $36.81 | 2,007,500 |
| 2026-06-17 | $34.82 | 3,098,800 |
| 2026-06-16 | $33.95 | 6,423,400 |
| 2026-06-15 | $35.21 | 933,700 |
| 2026-06-12 | $34.83 | 927,400 |
| 2026-06-11 | $33.93 | 1,063,800 |
| 2026-06-10 | $32.92 | 1,345,400 |
| 2026-06-09 | $34.06 | 1,354,100 |
| 2026-06-08 | $34.84 | 1,139,900 |
| 2026-06-05 | $35.59 | 2,961,900 |
| 2026-06-04 | $37.23 | 1,045,600 |
| 2026-06-03 | $36.21 | 1,444,400 |
| 2026-06-02 | $37.25 | 2,816,600 |
| 2026-06-01 | $40.26 | 4,468,600 |
| 2026-05-29 | $34.16 | 1,166,900 |
| 2026-05-28 | $33.30 | 1,772,900 |
| 2026-05-27 | $33.54 | 572,700 |
| 2026-05-26 | $33.56 | 1,339,100 |
| 2026-05-22 | $32.70 | 681,400 |
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
đ° Latest News
Edgewise Therapeutics Remains Compelling Cardiology Story Despite Atrial Fibrillation Concerns, RBC Says
MT Newswires âĸ 2026-06-17T15:02:54ZEdgewise Bounds Between Double-Digit Losses And Gain â What's Going On?
Investor's Business Daily âĸ 2026-06-16T20:06:20Z
Edgewise Therapeutics Reports Improvements In Heart Drug Trial
Benzinga âĸ 2026-06-16T17:40:12Z
SpaceX, Rackspace surge premarket; Edgewise Therapeutics, Huntsman fall
Investing.com âĸ 2026-06-16T12:44:12ZAssessing Edgewise Therapeutics (EWTX) Valuation After A Sharp Recent Share Price Move
Simply Wall St. âĸ 2026-06-02T16:10:42Z
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal
Zacks âĸ 2026-06-02T15:13:00Z
Servier to acquire Edgewiseâs muscular dystrophy business for $2.65bn
Pharmaceutical Technology âĸ 2026-06-02T09:32:58Z
How Edgewise Sweetened Its Coffers By $1.55 Billion, And Removed A Key Overhang
Investor's Business Daily âĸ 2026-06-01T20:31:10Z
EWTX Stock Hits Record High â Why Servier Is Shelling Out $2.65B For Edgewiseâs Muscular Dystrophy Business
Stocktwits âĸ 2026-06-01T14:03:01Z
Servier buys into muscular dystrophy with potentially $2.7B deal
BioPharma Dive âĸ 2026-06-01T11:39:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $191,406,000 | $158,832,000 | $114,357,000 | $71,658,000 |
| Net Non Operating Interest Income Expense | $23,611,000 | $25,019,000 | $14,194,000 | $4,018,000 |
| Operating Expense | $191,406,000 | $158,832,000 | $114,357,000 | $71,658,000 |
| General And Administrative Expense | $40,017,000 | $31,866,000 | $23,452,000 | $17,626,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-167,795,000 | $-133,813,000 | $-100,163,000 | $-67,640,000 |
| Net Interest Income | $23,611,000 | $25,019,000 | $14,194,000 | $4,018,000 |
| Interest Income | $23,611,000 | $25,019,000 | $14,194,000 | $4,018,000 |
| Normalized Income | $-167,795,000 | $-133,813,000 | $-100,163,000 | $-67,640,000 |
| Net Income From Continuing And Discontinued Operation | $-167,795,000 | $-133,813,000 | $-100,163,000 | $-67,640,000 |
| Total Operating Income As Reported | $-191,406,000 | $-158,832,000 | $-114,357,000 | $-71,658,000 |
| Net Income Common Stockholders | $-167,795,000 | $-133,813,000 | $-100,163,000 | $-67,640,000 |
| Net Income | $-167,795,000 | $-133,813,000 | $-100,163,000 | $-67,640,000 |
| Net Income Including Noncontrolling Interests | $-167,795,000 | $-133,813,000 | $-100,163,000 | $-67,640,000 |
| Net Income Continuous Operations | $-167,795,000 | $-133,813,000 | $-100,163,000 | $-67,640,000 |
| Pretax Income | $-167,795,000 | $-133,813,000 | $-100,163,000 | $-67,640,000 |
| Interest Income Non Operating | $23,611,000 | $25,019,000 | $14,194,000 | $4,018,000 |
| Operating Income | $-191,406,000 | $-158,832,000 | $-114,357,000 | $-71,658,000 |
| Per Share | ||||
| Diluted EPS | $-1.63 | $-0.42 | $-1.57 | $-0.31 |
| Basic EPS | $-1.63 | $-0.42 | $-1.57 | $-0.31 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-189,140,000 | $-156,542,000 | $-112,625,000 | $-71,120,000 |
| Reconciled Depreciation | $2,266,000 | $2,290,000 | $1,732,000 | $538,000 |
| EBITDA (Bullshit earnings) | $-189,140,000 | $-156,542,000 | $-112,625,000 | $-71,120,000 |
| EBIT | $-191,406,000 | $-158,832,000 | $-114,357,000 | $-71,658,000 |
| Diluted Average Shares | $102,930,744 | $94,721,769 | $63,723,600 | $63,231,580 |
| Basic Average Shares | $102,930,744 | $94,721,769 | $63,723,600 | $63,231,580 |
| Diluted NI Availto Com Stockholders | $-167,795,000 | $-133,813,000 | $-100,163,000 | $-67,640,000 |
| Research And Development | $151,389,000 | $126,966,000 | $90,905,000 | $54,032,000 |
| Selling General And Administration | $40,017,000 | $31,866,000 | $23,452,000 | $17,626,000 |
| Other Gand A | $40,017,000 | $31,866,000 | $23,452,000 | $17,626,000 |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $522,257,000 | $459,216,000 | $318,830,000 | $346,716,000 |
| Total Assets | $552,603,000 | $486,817,000 | $340,035,000 | $367,101,000 |
| Total Non Current Assets | $9,218,000 | $11,334,000 | $13,038,000 | $10,102,000 |
| Current Assets | $543,385,000 | $475,483,000 | $326,997,000 | $356,999,000 |
| Other Current Assets | $13,276,000 | $5,313,000 | $8,604,000 | $5,052,000 |
| Cash Cash Equivalents And Short Term Investments | $530,109,000 | $470,170,000 | $318,393,000 | $351,947,000 |
| Cash And Cash Equivalents | $61,148,000 | $41,666,000 | $86,097,000 | $21,993,000 |
| Other Non Current Assets | - | $262,000 | $348,000 | $251,000 |
| Prepaid Assets | - | - | - | $5,052,000 |
| Debt | ||||
| Total Debt | $3,990,000 | $4,737,000 | $5,414,000 | $4,408,000 |
| Long Term Debt And Capital Lease Obligation | $2,976,000 | $3,741,000 | $4,434,000 | $3,800,000 |
| Current Debt And Capital Lease Obligation | $1,014,000 | $996,000 | $980,000 | $608,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $30,346,000 | $27,601,000 | $21,205,000 | $20,385,000 |
| Total Non Current Liabilities Net Minority Interest | $2,976,000 | $3,741,000 | $4,434,000 | $3,800,000 |
| Current Liabilities | $27,370,000 | $23,860,000 | $16,771,000 | $16,585,000 |
| Payables And Accrued Expenses | $13,926,000 | $12,808,000 | $10,096,000 | $11,945,000 |
| Payables | $6,006,000 | $5,579,000 | $4,025,000 | $6,105,000 |
| Accounts Payable | $6,006,000 | $5,579,000 | $4,025,000 | $6,105,000 |
| Other Non Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $522,257,000 | $459,216,000 | $318,830,000 | $346,716,000 |
| Total Equity Gross Minority Interest | $522,257,000 | $459,216,000 | $318,830,000 | $346,716,000 |
| Stockholders Equity | $522,257,000 | $459,216,000 | $318,830,000 | $346,716,000 |
| Gains Losses Not Affecting Retained Earnings | $677,000 | $420,000 | $99,000 | $-1,355,000 |
| Other Equity Adjustments | $677,000 | $420,000 | $99,000 | $-1,355,000 |
| Retained Earnings | $-546,371,000 | $-378,576,000 | $-244,763,000 | $-144,600,000 |
| Preferred Securities Outside Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $106,249,579 | $94,838,466 | $70,453,342 | $63,257,376 |
| Share Issued | $106,249,579 | $94,838,466 | $70,453,342 | $63,257,376 |
| Tangible Book Value | $522,257,000 | $459,216,000 | $318,830,000 | $346,716,000 |
| Invested Capital | $522,257,000 | $459,216,000 | $318,830,000 | $346,716,000 |
| Working Capital | $516,015,000 | $451,623,000 | $310,226,000 | $340,414,000 |
| Capital Lease Obligations | $3,990,000 | $4,737,000 | $5,414,000 | $4,408,000 |
| Total Capitalization | $522,257,000 | $459,216,000 | $318,830,000 | $346,716,000 |
| Additional Paid In Capital | $1,067,941,000 | $837,363,000 | $563,487,000 | $492,665,000 |
| Capital Stock | $10,000 | $9,000 | $7,000 | $6,000 |
| Common Stock | $10,000 | $9,000 | $7,000 | $6,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $2,976,000 | $3,741,000 | $4,434,000 | $3,800,000 |
| Current Capital Lease Obligation | $1,014,000 | $996,000 | $980,000 | $608,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $12,430,000 | $10,056,000 | $5,695,000 | $4,032,000 |
| Current Accrued Expenses | $7,920,000 | $7,229,000 | $6,071,000 | $5,840,000 |
| Net PPE | $9,218,000 | $11,072,000 | $12,690,000 | $9,851,000 |
| Accumulated Depreciation | $-6,769,000 | $-4,685,000 | $-2,616,000 | $-1,065,000 |
| Gross PPE | $15,987,000 | $15,757,000 | $15,306,000 | $10,916,000 |
| Leases | $9,646,000 | $9,646,000 | $8,728,000 | $0 |
| Construction In Progress | $77,000 | $0 | $80,000 | $7,338,000 |
| Other Properties | $5,457,000 | $5,304,000 | $5,720,000 | $3,297,000 |
| Machinery Furniture Equipment | $807,000 | $807,000 | $778,000 | $281,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $468,961,000 | $428,504,000 | $232,296,000 | $329,954,000 |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-144,072,000 | $-110,340,000 | $-97,693,000 | $-58,181,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-143,816,000 | $-109,028,000 | $-91,948,000 | $-52,635,000 |
| Cash Flow From Continuing Operating Activities | $-143,816,000 | $-109,028,000 | $-91,948,000 | $-52,635,000 |
| Investing Activities | ||||
| Capital Expenditure | $-256,000 | $-1,312,000 | $-5,745,000 | $-5,546,000 |
| Investing Cash Flow | $-32,790,000 | $-184,656,000 | $102,886,000 | $-70,577,000 |
| Cash Flow From Continuing Investing Activities | $-32,790,000 | $-184,656,000 | $102,886,000 | $-70,577,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $187,362,000 | $239,147,000 | $52,618,000 | $129,165,000 |
| Financing Cash Flow | $196,088,000 | $249,253,000 | $53,166,000 | $129,639,000 |
| Cash Flow From Continuing Financing Activities | $196,088,000 | $249,253,000 | $53,166,000 | $129,639,000 |
| Net Common Stock Issuance | $187,362,000 | $239,147,000 | $52,618,000 | $129,165,000 |
| Common Stock Issuance | $187,362,000 | $239,147,000 | $52,618,000 | $129,165,000 |
| Net Other Financing Charges | - | $-262,000 | $-165,000 | $-251,000 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| End Cash Position | $61,148,000 | $41,666,000 | $86,097,000 | $21,993,000 |
| Beginning Cash Position | $41,666,000 | $86,097,000 | $21,993,000 | $15,566,000 |
| Changes In Cash | $19,482,000 | $-44,431,000 | $64,104,000 | $6,427,000 |
| Proceeds From Stock Option Exercised | $8,726,000 | $10,368,000 | $713,000 | $725,000 |
| Net Investment Purchase And Sale | $-32,534,000 | $-183,344,000 | $108,631,000 | $-65,031,000 |
| Sale Of Investment | $494,692,000 | $293,711,000 | $364,497,000 | $227,357,000 |
| Purchase Of Investment | $-527,226,000 | $-477,055,000 | $-255,866,000 | $-292,388,000 |
| Net PPE Purchase And Sale | $-256,000 | $-1,312,000 | $-5,745,000 | $-5,546,000 |
| Purchase Of PPE | $-256,000 | $-1,312,000 | $-5,745,000 | $-5,546,000 |
| Change In Working Capital | $-5,374,000 | $10,328,000 | $-1,560,000 | $4,086,000 |
| Change In Other Current Liabilities | $-748,000 | $-220,000 | $-104,000 | $2,920,000 |
| Change In Payables And Accrued Expense | $3,337,000 | $7,256,000 | $2,097,000 | $2,618,000 |
| Change In Accrued Expense | $3,065,000 | $5,519,000 | $2,189,000 | $2,571,000 |
| Change In Payable | $272,000 | $1,737,000 | $-92,000 | $47,000 |
| Change In Account Payable | $272,000 | $1,737,000 | $-92,000 | $47,000 |
| Change In Prepaid Assets | $-7,963,000 | $3,292,000 | $-3,553,000 | $-1,452,000 |
| Stock Based Compensation | $34,752,000 | $24,712,000 | $17,560,000 | $10,924,000 |
| Amortization Of Securities | $-7,665,000 | $-12,545,000 | $-9,517,000 | $-543,000 |
| Depreciation Amortization Depletion | $2,266,000 | $2,290,000 | $1,732,000 | $538,000 |
| Depreciation And Amortization | $2,266,000 | $2,290,000 | $1,732,000 | $538,000 |
| Depreciation | $2,266,000 | $2,290,000 | $1,732,000 | $538,000 |
| Net Income From Continuing Operations | $-167,795,000 | $-133,813,000 | $-100,163,000 | $-67,640,000 |
| Change In Other Working Capital | - | - | - | $1,235,000 |
Fetched: 2026-06-20